The Database
The market, already mapped.
Every human drug, trial, company, and disease, joined, enriched, and live. Track competitor pipelines, benchmark mechanisms across diseases, or review regulatory and commercial milestones.
Beta · Coming 2026Join waitlist
Pharma intelligenceused to be a procurement project.Now it's a login
Always-on intelligence in a new operating layer
Most pharma tools give you a database, a search bar, or a prompt box. You do the work.
LabWinds does the work upstream. An AI that learns and remembers what you care about, running around the clock. It maps and enriches the pharma market into one connected database, personalises it for you in a feed, and acts on it as your personal analyst.
You return to something already done.
Inside the login
The Feed
The news, already read.
A self-learning feed that opens like your curated pharma newspaper. Readouts, enrollment updates, leadership changes, deals, regulatory events, and R&D launches arrive already structured with a one-line so-what on each.
The Agent
The analyst, already working.
Not a chatbot. A pharma analyst you pair with. It learns what you're working on, sharpens as you use it, connects the dots into insights, prepares your morning brief, runs scheduled tasks overnight, and reaches you on email, Slack, or WhatsApp.
The platforms that own this market were built before AI existed
They cost $50,000+ a year.
They take six months to procure.
They still don't know who you are
LabWinds is the version that does
Your feed · today
Live · Apr 10
Commercial · M&A
Positive7:14 AM
Vertex acquires Alpine Immune Sciences for $4.9B, betting on povetacicept in IgA nephropathy.
So what · Vertex’s biggest non-CF bet to date. TACI/BAFF moves into renal immunology overnight.
VertexAlpine ImmunepovetaciceptIgA nephropathy
Study · Phase 3 readout
Positive readout6:02 AM
Amgen’s tarlatamab extends OS in ES-SCLC; DeLLphi-304 confirms DLL3 BiTE Phase 3.
AmgenImdelltraDLL3Small-cell lung cancer
Agent whisper · R&D
Two competitors on your watchlist filed PCT applications in NASH this week. Quick comparison ready when you want it.
Drug profile
Resmetirom
(Rezdiffra)Madrigal Pharmaceuticals
Target
THR-β
Thyroid Hormone Receptor β · ~28× selective over THR-α
Mechanism
Selective THR-β agonist
Liver-selective uptake · reduces hepatic lipotoxicity
Small moleculeOral · QD
Coverage
Trials
47Indications
1News
312Deals
3Analyst task · complete
4 rows · 23 sources“TROP2 ADC competitive landscape through 2026.”
AssetPhaseReadout
Datopotamab deruxtecan
AstraZeneca · Daiichi
Sacituzumab govitecan
Gilead
Sacituzumab tirumotecan
Merck (ex-Sumitomo)
Every entity traces to a source. Every classification traces to an article. Every Analyst answer cites the row.
Solutions
Three corners of pharma, one operating layer
Pharma teams arrive with different questions. Researchers chase mechanisms. Commercial teams chase movement. Consultants and leaders chase the right thing to read first. LabWinds is one platform that earns a seat in each of those working days.
Science & Medical
Read the mechanism, not just the headline
For pharmacologists, medical affairs, and clinical research teams who follow the science. Mechanisms read structurally, cohorts kept separate, every claim cited back to the trial, the label, or the paper.
- Drug profiles in five dimensions
- HGNC-canonical targets
- Polarity-correct disease cohorts
Commercial & Investing
First on the phone when the market moves
For BD, competitive intelligence, equity analysts, and biotech investors who read the market before the market reads itself. Competitor moves arrive already classified, ranked around your coverage, with a so-what that points forward.
- Competitor pipelines, subsidiaries folded
- Deals sliced by sector or target
- Forward-looking so-what on every story
Consulting & Leadership
Cover your portfolio without slowing down
For consultants and leaders with too many companies and not enough Tuesdays. LabWinds learns who you cover, briefs you overnight, pings your phone when the market moves. Reply in plain English: it drafts the email, sets the meeting, runs the report. No menus, no filters.
- Coverage learned, not configured
- Push alerts when the market moves
- Reply in plain English, it acts
Living, breathing, unified data
0drugs
0companies
0clinical trials
0diseases
0therapy areas
0news stories
A feed that gets to know you
Free pharma news is everywhere. Free pharma news that lands ready to act on is not.
- Category + subcategory. Twenty-one subcategories under six. Every card lands in the taxonomy.
- Entity chips. The drug, company, disease, mechanism, and trial behind it.
- Sentiment. Positive, negative, mixed, or neutral, with confidence.
- A forward-looking so-what. One line on what it means, not just what happened.
Specialist extraction, by event type
- On a readoutphase, endpoint, result
- On a filingregulatory pathway
- On a partnershipdeal structure
That structure is what lets the feed become yours.
The platform learns from how you work.
- What you read, click, ask, and return to.
- The assets on your beat, the indications you orbit, the companies you cover.
- Cards reorder around that picture: events that touch your work surface first, the rest fall away.
No list to manage
You don't manage a list. The feed builds one from how you work.
The longer you use it, the less of it you have to read. The free tier is genuinely free, no signup needed. Sign in, and the picture sharpens.
Study news
Positive readout
BioNTech's BNT327 hits primary endpoint in NSCLC Phase 2; ORR 38% vs 14% control.
So what · PD-L1×VEGF bispecifics are the most-watched class in NSCLC right now. This is the cleanest readout in the space this quarter.
Commercial · M&AChapter 14
The GLP-1 Wars — Novo files for injunction against Lilly's tirzepatide expansion.
14 / 14
Agent whisper · R&D
Three companies on your watchlist made non-opioid pain pipeline moves this month. The space is heating up — I put together a quick competitive view.
Six categories · Twenty-one subcategories
Study News
2 subClinical Trial NewsReal World EvidenceAI in Study DesignCommercial Deals
4 subM&AFinancingService AgreementsStrategic PartnershipsAI-Related DealsProduct News
3 sub · 2 specialistProduct SpecsProduct SalesProduct Clinical & RegulatoryAI in Drug DiscoveryR&D News
4 sub · 2 specialistProjectsInfrastructurePublicationsIP & RegulatoryAI in R&DCorporate
3 sub · 1 specialistLeadershipGovernance & FinanceProceduralFinancial
5 sub · 1 specialistForecastsPerformanceStock DataComplianceCapital Structure
The pharma market, joined up
Roche Holding AGPharma · Public · 33 subsidiaries
33 subsGenentech·Chugai·Carmot Therapeutics·+30 moreGenentech · Chugai · +31
Include subs
Drugs
Pipeline
Trials
Deals
Regulatory
Leadership
MechanismP1P2P3APPROVED
- Anti-PD-L12311
- ADC4632
- Bispecific32··
- Anti-CD20·124
- Anti-HER2·213
View full pipeline →
HER2+ Breast CancerParent · Breast cancer
Disease taxonomy · lineage
- Oncology
- Cancer
- Organ system cancer
- Thoracic cancer
- Breast cancer
- HER2+ Breast Cancer
Overview
Drugs
Trials
Regulatory
Deals
News
Approved drugs (8)top 5 shown
- TrastuzumabHerceptinmAb
- PertuzumabPerjetamAb
- T-DXdEnhertuADC
- T-DM1KadcylaADC
- TucatinibTukysaTKI
Active trials by drug class188 active
mAbs97TKIs102ADCs69Bispecifics6
Scope · polarity handled
HER2-positive cohort only. HER2-negative and triple-negative tracked separately under their own entities.
The LabWinds database is the joined-up working picture of the pharma market: every human therapeutic drug, the companies behind them, the diseases they target, the trials testing them, the labels approving them, the regulatory events shaping them, the deals moving them, the news changing their story. Each fact enriched from multiple authoritative sources, verified against itself, traced to its origin.
- Drugs. Characterised five ways: class, modality, target, mechanism, therapeutic intent.
- Targets. Resolved to canonical HGNC gene symbols. A query for BCMA finds every bispecific listing TNFRSF17.
- Companies. Harmonised into operating brands and ultimate parents. Genentech and Chugai roll up under Roche.
- Diseases. A curated multi-level hierarchy mapped to 17 therapeutic areas, with polarity handled. HER2-positive, HER2-negative, and triple-negative are distinct cohorts.
- Indications. Approved come from drug labels. Experimental come from clinical trials. Both carry biomarker, line of therapy, and combination context.
Every entity profile is synthesised across the lot.
Joined data is what makes the questions worth asking.
- Map a company's pipeline by phase, mechanism, and indication, with subsidiaries folded in.
- Benchmark competitors across a target class.
- Landscape a disease end-to-end: approved drugs, experimental trials, regulatory journeys, deal flow, and the news that moved them.
- Trace any asset's regulatory journey from IND through approval.
- Filter deals by type, mechanism, indication, geography, or buyer sector.
- Watch trend lines on a mechanism or modality over years.
Live, not delayed
News often lands before the trial registries update. The data layer pushes trial state forward as readouts happen: enrollment shifts, endpoint hits, status changes. Not when the registry catches up.
The version of this that enterprises pay $50,000+ a year for is locked behind a procurement contract. The version you can use right now isn't.
Deals DatabasePartnerships · M&A · Financings · Service agreements · updated dailyPartnerships · M&A · Financings
Filter by
Active filters · 8
Saved view ▾+ Filter
PartnershipAI / MLCo-DevelopmentOncologyValue ≥ $1BUnited States2024Status: Announced
Top deals · sorted by value↓ Value
PartiesTypeStage / AssetValueStatusDate
- Schrödinger×NovartisCo-DevelopmentAI / MLMulti-target discovery$4.6B$150M upfrontAnnouncedNov 12, 2024
- Monte Rosa Therapeutics×NovartisLicensingAI / MLMGD platform$2.25B$150M upfrontAnnouncedOct 28, 2024
- insitro×Bristol Myers SquibbAI TechnologyAI / MLTarget ID · ALS$2.05B$50M upfrontAnnouncedDec 18, 2024
- Flare Therapeutics×RocheCo-DevelopmentAI / MLTranscription factors$1.87B$70M upfrontAnnouncedNov 14, 2024
- Schrödinger × Novartis$4.6B$150M upfrontCo-DevelopmentAI / ML· Multi-target discoveryAnnouncedNov 12, 2024
- Monte Rosa Therapeutics × Novartis$2.25B$150M upfrontLicensingAI / ML· MGD platformAnnouncedOct 28, 2024
- insitro × Bristol Myers Squibb$2.05B$50M upfrontAI TechnologyAI / ML· Target ID · ALSAnnouncedDec 18, 2024
- Flare Therapeutics × Roche$1.87B$70M upfrontCo-DevelopmentAI / ML· Transcription factorsAnnouncedNov 14, 2024
Open any deal for the full profile: parties, milestone schedule, IP terms, territorial rights, advisors, market reaction.View all deals →
Entity resolutiondrug_id · 0d3a9c
OzempicWegovyRybelsus+ 44semaglutidecanonical
1,247articles across all aliases
An analyst that works
the hours you don't
Not a pharma chatbot. The LabWinds Analyst runs against the resolved database, plans the steps, picks the tools, and cites every claim back to the row it came from. It learns what you're working on between sessions, and works while you're not in the app.
- Domain specialist. Skill cookbooks teach the agent how to think about drugs, companies, diseases, trials, deals, labels, and regulatory events. Not one system prompt.
- Specialist tools. Callable tools beyond text: compare drugs by biomarker, landscape a target class, pull a company pipeline with subsidiaries folded in. Simple lookups route fast; multi-step analysis escalates to deeper models.
- Persistent memory. Per-user facts, watchlists, and working context carry between sessions. No preferences screen. It learns from what you read, ask, return to, and correct.
- Grounded, not guessed. Every factual line cites the trial NCT, the drug label, the news article, the publication, the row. A query ledger records the filters actually applied, so the agent can't quietly broaden a claim.
Example analyst queries, by shape
- "GLP-1 obesity pipeline by readout date"ranked table, cited per row
- "Brief me on Novartis before Thursday"400-word brief
- "What moved on my watchlist overnight"3 movements, ranked
It doesn't wait for you to ask.
Three jobs run continuously.
- Pulls together your Morning Brief overnight, ordered by what's on your watchlist.
- Runs scheduled tasks in plain English: 'every Friday, oncology deals from this week.'
- Whispers when something on your beat moves. Stays quiet when nothing does.
- Picks up where you are. Open a drug profile and ask 'how does this compare to last quarter' — it already knows the drug.
Meeting prep, while you sleep
Ask the analyst to brief you on Novartis before Thursday's customer call. By 6am, it's pulled the pipeline movements, regulatory events, deal activity, and three things that changed since you last asked, with citations on every line.
On your desk during the day. In your pocket on the train. On your watchlist while you sleep.
Join the waitlist01Morning brief
Today's briefing
7:03 AMHero story
Vertex's VX-548 clears Phase 3 in acute pain — first non-opioid to do so in 15 years.
Why this matters · You flagged Vertex two weeks ago. The hazard ratio is the cleanest non-opioid signal we've seen this cycle — relevant to your BD call at 10am.
VX-548Vertex PharmaceuticalsAcute pain
02Scheduled task
Overnight watchlist scan
CompleteRan 03:42 · 47 events flagged · 3 surfaced
Next run · tomorrow 03:30
03Reached you on
Slack#watchlist · just now
LabWinds Agent BNT327 Phase 2 readout just published — competitive view for NSCLC ready.
Emailagent@labwinds · 8:14 AM
Your watchlist · 3 movements you'll want to see
PushiOS · 12 min ago
Vertex VX-548 cleared Phase 3.
04Analyst query
Working
Complexity: Tier 2You · 09:14
Compare Keytruda vs Opdivo PD-L1 trials in NSCLC.
Analyst
ROUTEdrug_biomarker_compare · conf 0.92
RECALL“you've been comparing PD-1/PD-L1 inhibitors this week”
WORKFLOWprefers ranked tables · withdrawn drugs flagged · concise summaries
RESOLVEKeytruda → pembrolizumab (+11 aliases) · Opdivo → nivolumab (+11 aliases)
SKILLdrugs cookbook · multi-target structure, status caveats
TOOLcompare_drugs_by_biomarker(biomarker=PD-L1, indication=NSCLC)
class verification: anti-PD-1 (not direct PD-L1) — caveat surfaced
Drug labels · 6 approved indications across both drugs · 4 NSCLC
Study database · 27 trials stratified by biomarker cutoff (TPS, CPS, IHC)
LEDGERentry #4 written · filters [PD-L1, NSCLC] · predicate guard ✓
Answer ↓
Keytruda holds the first-line NSCLC monotherapy slot. Approved when PD-L1 TPS ≥ 50% (KEYNOTE-024 NCT02142738) and later extended to TPS ≥ 1%. Opdivo's first-line approval is combination-only, with
London · EC
About
Built by people who have lived the problem.
LabWinds is built by a small team of pharma operators, data scientists, and AI engineers who have worked inside the industry and across the platforms that serve it. We have seen what the $50-100K+ a-year incumbents do brilliantly. We have also seen where they leave you stranded.
We have watched colleagues open Google or ask Claude on a Tuesday afternoon, because the dedicated tool was slower than the open web. With access to the most expensive intelligence platforms on the market, that should not be the answer.
So we set out to build the answer. A platform that knows the pharma market, learns your beat, and works the hours you do not. That is LabWinds.
Proudly British. Based in London. Serving a global market.
Pharma intelligence, on a credit card.
No procurement. No contract. No six-month pilot.
Start with the feed — it's free.